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Abstract  
BACKGROUND: While treatment-resistant and non-treatment-resistant depressed patients show 
structural brain anomalies relative to healthy controls, the difference in regional volumetry between 
these two groups remains undocumented. 
METHODS: A whole-brain voxel-based morphometry (VBM) analysis of regional volumes was 
performed in 125 participants’ MR images obtained on a 1.5 Tesla scanner; 41 had treatment-resistant 
depression (TRD), 40 non-treatment-resistant depression (non-TRD), and 44 were healthy controls. The 
groups were comparable for age and gender. Bipolar/unipolar features as well as pharmacological 
treatment classes were taken into account as covariates.  
RESULTS: TRD patients had higher gray matter (GM) volume in the left and right amygdala than non-
TRD patients. No difference was found between the TRD bipolar and the TRD unipolar patients, or 
between the non-TRD bipolar and non-TRD unipolar patients. An exploratory analysis showed that 
lithium-treated patients in both groups had higher GM volume in the superior and middle frontal gyri in 
both hemispheres.  
CONCLUSIONS: Higher gray matter volume in amygdala detected in TRD patients might be seen in 
perspective with vulnerability to chronicity, revealed by medication resistance. 
 
 
 
 
Introduction 
 
Treatment-resistant depression occurs in 20% to 30% of depressed patients and leads to severe disability 
(Greden 2001). Treatment-resistant depression (TRD) is a condition in which the patients fail to respond 
to at least two trials with antidepressants from different pharmacological classes or do not evolve 
favourably under the influence of the treatment (Little 2009, Duhameau et al. 2010, Kubitz et al. 2013). 
Although Major Depressive Disorder (MDD) has been scrutinized by neuroimaging studies (Konarski 
et al. 2006, Koolschijn et al. 2009, Lorenzetti et al. 2009, Price, Drevets 2010), fewer magnetic 
resonance (MR) studies have examined the brain structure in TRD versus non-treatment-resistant 
depression (non-TRD) (McIntyre et al. 2014).  
Smaller gray matter volume in several frontal and temporal regions, may confer vulnerability to or 
characterize patients with TRD (Furtado, Maller & Fitzgerald 2008, Li et al. 2010, Shah et al. 1998, 
Shah et al. 2002). Larger GM volumes have also been observed, notably in the temporal cortex 
regions, including the parahippocampus and amygdala (Li et al. 2010), although this has not been 
constantly replicated (Zhou et al. 2011). Further MR brain morphometry analysis is warranted given 
the scarcity of studies of these latter regions involved in emotional regulation.  
Indeed, other MR modalities in TRD patients suggest changes in amygdala and related regions. Higher 
resting-state hippocampus-amygdala blood flow was found in TRD patients compared to patients with 
non-TRD in a single photon emission computed tomography study (SPECT) (Hornig, Mozley & 
Amsterdam 1997). Furthermore, arterial spin labelling perfusion MRI showed hyperperfusion in the 
TRD and chronically depressed patients, in the left subcortical regions (amygdala, putamen and 
pallidum), together with the left dorsomedial prefrontal, left anterior cingulate cortex (ACC) (Duhameau 
et al. 2010). Also, reduced functional connectivity within the left amygdala to anterior cingulate was 
reported, when comparing TRD to non TRD (Lui et al. 2011). Reduced magnetization transfer ratio was 
observed in the amygdala-parahippocampal areas, caudate, anterior cingulate, and insula, in the right 
hemisphere, in the TRD group relative to healthy controls, but voxel-based morphometry (VBM) 
analyses did not reveal any morphological difference between these groups (Zhang et al. 2009).  
The involvement of specific brain regions in TRD was furthermore suggested by the improvement of 
clinical conditions obtained through repetitive transcranial magnetic stimulation in dorsolateral 
prefrontal cortex (Paillere Martinot et al. 2011) or through deep brain stimulation in subcallosal 
cingulate (Holtzheimer, Mayberg 2010).  
Thus the pathogenesis of TRD is still under debate; it could have structural (Li et al. 2010) and/or 
functional determinants being attributed to abnormal neural activity in multiple brain regions (Lui et al. 
2011, Guo et al. 2011, Kumari et al. 2003). Notably, abnormalities in limbic regions may play a role in 
the pathophysiology of treatment-resistance (Hornig, Mozley & Amsterdam 1997), in the foreground of 
which the amygdala - hippocampus complex. 
 
There is a limited number of studies regarding the differences of brain morphometry between TRD and 
non-TRD patients (McIntyre et al. 2014) and even inconsistencies of findings (Shah et al. 2002, Zhou 
et al. 2011), that were sometimes driven by a region of interest approach. Based on a previous study by 
our group (Paillere Martinot et al. 2011) reporting higher fluoro-deoxyglucose metabolism (FDG) in the 
amygdala associated with decreased FDG in the orbitofrontal cortex in TRD patients resistant to 
repetitive transcranial magnetic stimulation, we searched for frontal-limbic structural abnormalities in 
TRD. The purpose of our study was to compare patients with TRD or non-TRD, and healthy controls 
using whole-brain voxel based morphometry (Ridgway et al. 2008, Ashburner, Friston 2000) of regional 
volumes.  
 
Methods 
The local ethics committees (APHP Salpêtrière and Bicêtre hospitals) approved the protocol of the 
study, and each participant provided written informed consent before inclusion in the studies.  
 
Participants 
We pooled datasets obtained from 125 participants enrolled in previous brain imaging protocols. 
Detailed demographic and clinical characteristics have been reported elsewhere (Paillere Martinot et al. 
2011, Penttila et al. 2009). Briefly, we recruited patients from consecutive admissions at an outpatient 
clinic and 6 psychiatry wards of university hospitals in Paris, France. Experienced senior psychiatrists 
established the patients’ diagnoses using the DSM-IV and the Mini- International Neuropsychiatric 
Interview. We also recruited healthy controls by word of mouth, and enrolled them at the same time as 
the patients. They had no personal history of psychiatric or neurological disorders, as assessed by the 
Mini-International Neuropsychiatric Interview and a medical examination.  
Treatment-resistance was defined as the lack of response to at least 2 antidepressants from different 
pharmacologic classes taken for at least 1 month in adequate dosages (Berlim, Turecki 2007).  
Non-TRD patients were in remission from a major depressive episode. Both unipolar and bipolar 
patients were considered in both TRD and non-TRD groups (Table 1).  
At the time of scan most of the patients received treatment (74/81); they were taking antidepressant 
medications, anticonvulsants, lithium, antipsychotics, or benzodiazepines (Table 1). There were only 3 
non-medicated patients in the TRD group and 4 in the non-TRD group during data acquisition. 
 
Image acquisition 
Magnetic resonance imaging (MRI) high-resolution T1-weighted images were acquired with a 3D-MRI 
sequence (124 contiguous slices; field of view 24cm; 256x256 matrix; voxel size: 0.94×0.94×1.3mm3 
or 0.86×0.86×1.2 mm3), TE=2 ms, TR=10 ms, TI=600 ms, flip angle=10°, and read bandwidth=12.5 
kHz on a 1.5 Tesla GE Signa scanner (General Electrics Medical Systems, Milwaukee, WI, USA). 
 
Voxel-based morphometry 
Data were processed and examined using the Statistical Parametric Mapping software (SPM8, 
http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). To study the morphometric changes in the depression 
groups (responders and non-responders to the treatment) versus controls, VBM was performed using 
the unified segmentation implemented in SPM8 (Ashburner, Friston 2005). T1-weighted images were 
spatially normalized and segmented using the “new segmentation” toolbox with the extended tissues 
probability maps. Afterwards VBM implemented in the VBM8 toolbox was applied 
(http://dbm.neuro.uni-jena.de/vbm8/) using clean-up segmentation and de-noising with non-local means 
filters for “write already estimated segmentation”.  
Finally, the modulated GM images were smoothed with a Gaussian kernel of 10 mm full-width half-
maximum (FWHM) isotropic Gaussian kernel. 
 
Statistics 
Demographic and clinical variables were analyzed within JMP software (http://www.jmp.com), using 
ANOVA, Khi2 or t tests as necessary. 
Imaging data were analysed using SPM8 software and General Linear model. Voxel-wise GM 
differences between the patient groups and controls were examined using one way ANOVA. In order to 
answer to both primary and exploratory questions, the model included five groups (unipolar TRD, 
bipolar TRD, unipolar non-TRD, bipolar non-TRD, and healthy controls). Age, total intracranial volume 
(TIV), gender, voxel size, and the treatment (antidepressants, lithium, anticonvulsants used as mood 
stabilizers, antipsychotics, benzodiazepine) were entered in the analysis as covariates. 
Primary analyses compared MDD (including TRD and non-TRD) patients versus controls, then TRD 
patients versus non-TRD patients. We also searched for differences between UP and BP TRD patients, 
and between UP and BP non-TRD patients respectively.  
Secondary analyses explored the effect of treatments in the whole group of patients. 
For all analyses height threshold was set at p<0.001, and extent threshold at p<0.05 (600 voxels) with 
family-wise error (FWE) correction for multiple spatial comparisons at the cluster level across the whole 
brain. 
 
Results  
Demographic and medication characteristics for subjects with MDD and healthy controls are reported 
in Table 1. TRD patients had significantly higher depression scores (MADRS) than non-TRD patients. 
Also, the non-TRD patients were more likely to have bipolar depression. No other between group 
difference was found, particularly regarding medications.  
 Primary analyses 
The whole MDD patient group (vs control group) exhibited reduced GM volume in the right anterior 
cingulate (Table 2). Larger GM volume was found in bilateral amygdala in TRD patients as compared 
to non-TRD patients (Figure 1 and Table 2). No difference was found between UP and BP TRD patients, 
nor between UP and BP non-TRD patients.  
Secondary analyses 
The patients on lithium showed larger GM volumes in superior and middle frontal gyri bilaterally, when 
compared to patients not on lithium (Figure 2 and Table 2).  
No significant difference was found with the other treatments. 
 
Discussion 
The comparison between patients with TRD and non-TRD motivated by the scarce information in the 
literature revealed a higher GM volume of the amygdala in the TRD patient group, while there was no 
difference in amygdala volumes between the whole depressed patient group and healthy controls. In 
addition, the greater amygdala volume in TRD patients was independent, irrespective of whether the 
patients presented bipolar or unipolar features. The depressed patients as a whole also exhibited reduced 
GM volume of the right anterior cingulate. The neurotrophic effect of the treatment with lithium was 
underlined once more by the current study showing higher GM volume in the superior and middle frontal 
gyri in the patients treated with lithium.  
Herein, the reduction of GM volume in the right anterior cingulate in the whole MDD group, replicates 
the literature on MDD and anatomical MRI. The most consistent finding in MDD is indeed GM 
reduction in the anterior cingulate cortex (ACC) (Konarski et al. 2006, Caetano et al. 2006, Du et al. 
2012, Tang et al. 2007, Treadway et al. 2009, Yucel et al. 2008). The evidence for reductions in other 
regions within fronto-subcortical and limbic regions is less consistently reported (Du et al. 2012, Bora 
et al. 2012). The current comparison consolidates once more the association between MDD and reduced 
GM density in ACC, and supports Drevets et al.’s (1997) conclusion that despite treatment with 
antidepressant medication, the reduction in subgenual ACC volume still persists.  
 
TRD is modelled as a failure of brain homeostatic mechanisms; the frontal lobes would be less active 
while the limbic regions, and notably the amygdala (involved in emotional processing and autonomic 
reactivity), would be overactive during depression (Giacobbe, Mayberg & Lozano 2009). Lui et al. 
(2011) found a higher connectivity in the TRD group with respect to the non-TRD within the left 
amygdala-anterior cingulate cortex-right insula-precuneus region. A seminal historical study (Hornig, 
Mozley & Amsterdam 1997) among the few that did a direct comparison between the TRD and non-
TRD is also consistent with our findings of higher hippocampus-amygdala blood flow in TRD than in 
non-TRD patients. Here, the direct comparison between non-TRD and TRD groups highlights the 
difference in amygdala volume.  
Amygdala, which plays a crucial role in modulating human emotion (Hamilton, Siemer & Gotlib 2008) 
has been extensively investigated with neuroimaging in affective disorders. Reviews of the literature, 
however, report the most conflicting findings depending on the stage of the disorder (Kubitz et al. 2013, 
Hamilton, Siemer & Gotlib 2008, Bellani, Baiano & Brambilla 2011). Only one VBM study in TRD 
patients has reported differences in amygdala volumes (Li et al. 2010). The authors found, in line with 
our results, a larger GM volume in the right amygdala, in the non-remitting patients when compared 
with those who achieved remission, although at a lenient, uncorrected statistical threshold.  
Differences in regional brain volumes have previously been hypothesized between patients able to 
achieve remission and those refractory to antidepressants. A study found atrophy in the right 
frontostriatal region in TRD, but the authors did not attempt to measure amygdala separately and the 
treatment status was not controlled between the TRD and non-TRD patient groups (Shah et al. 2002).  
In contrast with our results, Lorenzetti et al. (2010) found a larger left amygdala in non-TRD remitted 
MDD patients when compared to healthy controls, while other investigators showed a larger amygdala 
in the healthy control group when compared to MDD patients (Keller et al. 2008, Kronenberg et al. 
2009). Another study has shown smaller hippocampal volumes in TRD patients relative to controls 
contrasting with our results that show no difference (Joshi et al. 2016). Interestingly in this study, smaller 
hippocampal and larger amygdala volumes associated with response to subsequent ECT treatment, 
which further increased amygdala volume (Joshi et al. 2016, Ten Doesschate et al. 2014). Thus the 
question arises whether changes in amygdala volume in MDD are a trait characteristic of the disease or 
are related to disease progression, chronicity, or medication. Enlarged amygdala volumes have also been 
reported in first-episode depressed patients (van Eijndhoven et al. 2009), with a positive correlation with 
the severity of depression. However, both increased (Frodl et al. 2002, Frodl et al. 2003) and decreased 
(Bora et al. 2012) amygdala volumes have been reported in first-episode MDD. Thus, in perspective 
with this literature, our findings raise, on one side, the question whether larger amygdala volumes might 
indicate vulnerability to develop medication resistance, on the other side, changes in amygdala volumes 
might be a consequence of affective disease progression per se, (Bora et al. 2012, Singh, DelBello & 
Chang 2012).   
 
Additionally, other factors that might influence amygdala volume include comorbid anxiety (Caetano et 
al. 2007) and medication, particularly mood stabilizers that are supposed to exert a neurotrophic effect 
(Price, Drevets 2010, Savitz et al. 2010). Meta-analytical studies by Hamilton, Siemer & Gotlib (2008) 
and Price and Drevets (2010) have indicated that studies focussing on only non-medicated depressed 
patients showed significantly lower amygdala volume in the depressed group when compared to 
controls, whereas studies in which all depressed patients were receiving adequate medication showed 
significantly larger amygdala volumes in the depressed group (Weniger, Lange & Irle 2006).  
A particularity in the present study is that both groups (TRD and non-TRD) received treatment and one 
could hypothesise that the treatment received by TRD during recurrent episodes of illness may have had 
a cumulative neurotrophic effect reflected through a larger amygdala, even if the clinical features had 
not significantly improved. However, ongoing medication was included here as a covariate in the 
statistical analysis; thus it is unlikely that the findings would relate to medication only.  
Furthermore, the finding of our exploratory comparison in patients (TRD and non TRD) treated with 
lithium vs patients without lithium advocates against a unique effect of medication on the amygdala 
volumes. We observed a higher GM volume in the superior and middle frontal gyri bilaterally, in patients 
with lithium. Moore et al. (2009) also found a significant increase in GM volume in the prefrontal cortex 
related to lithium treatment. These results emphasize the purported neurotrophic effect of lithium 
(Quiroz et al. 2010), notably on the prefrontal cortex. However, the neurotrophic effect of lithium in the 
present study did not account for the higher GM volume in amygdala, since the comparison of lithium 
and non-lithium treated patients did not yield results in these regions.  
Given the heterogeneous nature of depression (Wager, Woo 2017), it is possible that other factors that 
were not studied in our work may yet influence findings. For example, some recent work (Wager, Woo 
2017, Drysdale et al. 2017) has shown that distinct depression connectivity biotypes may determine 
treatment responsiveness. Also, disease course (age of onset, number of depressive episodes) may 
contribute to variations in brain morphology. However, in our study no relation was found between age 
of onset or duration of illness, and amygdala volume.  
Still, a main limitation of the present study is that it cannot disentangle whether the larger amygdala 
volume relates to vulnerability or develops through the course of the disease. Indeed, the cross sectional 
design of the study makes it difficult to determine whether a larger volume indicates a risk factor for 
TRD from the onset of illness, or whether it is a consequence of the failure of brain homeostatic 
mechanisms (e.g. overactive amygdala) related to comorbid anxiety during depression.  
Also, patients with bipolar and unipolar depression were pooled in this study. Differences in amygdala 
volumes might have blurred the results, as larger amygdala volumes have been reported in adults with 
bipolar disorder (Strakowski 2012), while reduced amygdala volumes have been found in adolescent 
patients with bipolar disorder (Pfeifer et al. 2008). In the present study, however, there was no difference 
between the TRD BP patients and the TRD UP patients, and no difference between the non-TRD UP 
and BP patients, indicating a similar pattern regarding amygdala volumes in UP and BP patients. 
Conclusions 
Overall, this study found that TRD patients exhibit larger GM amygdala volumes. This increase was not 
related to medication or to bipolar or unipolar status, and might provide a neuroimaging biomarker of 
vulnerability to chronicity, revealed by medication resistance. 
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 Table 1: Demographic and medication characteristics for subjects with MDD and healthy controls 
 
 
Demographic and  
medication characteristics  
MDD patients 
N=81 
Healthy subjects 
N=44 
p 
    
TRD 
N=41 
Non-TRD 
N=40 
  
     
     
Age (years), mean ± SD 47.15 ± 8.06 46.10 ± 9.62 46.42 ±10.08 0.87 
Age range, years 29 - 59.5 29 - 63 28.5 - 62  
Gender, male, N (%) 15 (36.59) 22 (55.00) 23 (52.27) 0.19 
Age of Onset, mean ± SD 28.26 ± 9.92 28.06 ± 10.90 - 0.93 
Duration of Illness, mean ± SD 18.90 ± 9.21 18.01 ± 11.56 - 0.71 
MADRS, mean ± SD 34.20 ± 7.19 12.70 ± 13.78 - <0.001 
Unipolar depression N (%)1 26 (63.41) 16 (40.00) -  
Bipolar depression, N (%) 2 15 (36.59) 24 (60.00) - 0.03 
     
Antidepressants/SSRIs N (%) 19 (46.34) 23 (57.50) - 0.31 
Anticonvulsants N (%) 12 (29.27) 10 (25.00) - 0.67 
Lithium N  (%) 5 (12.20) 10 (25.00) - 0.14 
Antipsychotics N  (%) 16 (39.02) 9 (22.50) - 0.11 
Benzodiazepine  N (%) 18 (43.90) 15 (37.50) - 0.56 
 
1 TRD unipolar patients (34.6 % male, mean age 45.4 ±9.3); non-TRD unipolar patients (50% male, 
mean age 42.3 ±7.53) 
2 TRD bipolar patients (40.00 % male, mean age 45.7 ±6.32); non-TRD bipolar patients (58.3% male, 
mean age 48.6±10.15) 
Abbreviations: SD, standard deviation; SSRIs, selective serotonin reuptake inhibitors; MDD, Major 
depressive disorder; TRD, treatment resistant depression; p, p value (ANOVA, Khi2 or t test) 
 
 
 
 
 
 
Table 2: Regional gray matter density differences in whole-brain voxel-based comparisons.   
 
    Cluster Peak level 
    MNI coordinates   
Region Side k p FWE x y z pa t 
TRD > non-TRD            
         
Amygdala Right 1145 0.006 28 4 -20 2.32E-06* 4.82 
Superior temporal gyrus  Right   40 -1 -15 5.87E-06 4.59 
         
Amygdala Left 791 0.029 -34 2 -18 1.92E-05 4.35 
         
HC > MDD                 
         
Anterior Cingulate Right 659 0.052 2 34 19 5.85E-06 4.59 
         
BP TRD vs UP TRD 
 
No suprathreshold voxel in any comparison 
 
BP nonTRD vs UP nonTRD 
 
No suprathreshold voxel in any comparison 
 
Li > non-Li         
         
Middle/Superior frontal gyrus Left 2746 <0.001 -21 53 31 5.66E-07* 5.15 
Superior Frontal /Sub-gyral Left   -22 9 45 1.55E-06* 4.92 
Middle frontal gyrus Left   -27 54 24 1.75E-06* 4.89 
         
Middle frontal gyrus Right 1977 <0.001 45 23 37 5.62E-06 4.60 
Middle/Superior frontal gyrus Right   38 17 54 1.82E-05 4.30 
Middle frontal gyrus Right     39 2 54 1.92E-05 4.29 
         
 
Abbreviations: TRD > non-TRD, comparison between treatment-resistant and non-resistant depression 
groups; HC > MDD, comparison between healthy controls and major depressive disorder patients (TRD 
and non TRD); BP, bipolar; UP, unipolar; Li > non-Li, comparison between MDD patients treated with 
lithium and patients without lithium; k = cluster size, expressed in number of voxels ; MNI = Montreal 
neurological Institute coordinates in millimeters; MNI coordinates are given for the voxel of maximal 
statistical; t, Student test value. 
p FWE. Cluster extent threshold p<0.05 Family Wise Error (FWE) corrected 
pa. Height threshold p<0.001 uncorrected; * Height threshold p<0.05 Family Wise Error (FWE) 
corrected. 
 
  
FIGURE 1 Whole-brain voxel-based morphometry (VBM) comparison between treatment-resistant 
(TRD) patients and non-resistant depression (non-TRD). TRD patients show higher gray matter volume 
in amygdala (red). Images are presented with height threshold P <0.001 and FWE correction for multiple 
spatial comparisons across the whole brain 
 
 
 
 
FIGURE 2 Whole-brain voxel-based morphometry (VBM) comparison between patients (TRD and not 
TRD) treated with lithium and patients without lithium. Lithium-treated patients show higher gray 
matter volume (red) in the superior and middle frontal gyri, bilaterally, when compared with patient 
group without lithium. Images are displayed with height threshold P < 0.001, and FWE correction for 
multiple spatial comparisons across the whole brain 
